vs

Side-by-side financial comparison of AST SpaceMobile, Inc. (ASTS) and X4 Pharmaceuticals, Inc (XFOR). Click either name above to swap in a different company.

AST SpaceMobile, Inc. is the larger business by last-quarter revenue ($54.3M vs $28.8M, roughly 1.9× X4 Pharmaceuticals, Inc). X4 Pharmaceuticals, Inc runs the higher net margin — 1.0% vs -136.2%, a 137.2% gap on every dollar of revenue.

AST SpaceMobile, Inc. is a publicly traded satellite designer and manufacturer based in Midland, Texas, United States. The company is building the SpaceMobile satellite constellation, a space-based cellular broadband network designed to connect directly to standard, unmodified smartphones. The network is intended to deliver 4G and 5G broadband coverage globally, particularly in remote and underserved regions.

X4 Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel targeted therapies for rare immunological diseases and oncology indications with high unmet medical needs. It operates primarily across the U.S. and European markets, with a lead pipeline candidate for WHIM syndrome and multiple other preclinical and clinical assets for immune disorders and cancer.

ASTS vs XFOR — Head-to-Head

Bigger by revenue
ASTS
ASTS
1.9× larger
ASTS
$54.3M
$28.8M
XFOR
Higher net margin
XFOR
XFOR
137.2% more per $
XFOR
1.0%
-136.2%
ASTS

Income Statement — Q4 FY2025 vs Q1 FY2025

Metric
ASTS
ASTS
XFOR
XFOR
Revenue
$54.3M
$28.8M
Net Profit
$-74.0M
$282.0K
Gross Margin
83.6%
Operating Margin
-175.0%
-32.8%
Net Margin
-136.2%
1.0%
Revenue YoY
2758.2%
Net Profit YoY
-106.3%
100.5%
EPS (diluted)
$0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASTS
ASTS
XFOR
XFOR
Q4 25
$54.3M
Q3 25
$14.7M
Q1 25
$28.8M
Q1 24
$0
Q4 23
$0
Q3 23
$0
$0
Q2 23
$0
$0
Q4 22
$-1.0K
Net Profit
ASTS
ASTS
XFOR
XFOR
Q4 25
$-74.0M
Q3 25
$-122.9M
Q1 25
$282.0K
Q1 24
$-51.8M
Q4 23
$-31.9M
Q3 23
$-20.9M
$-2.3M
Q2 23
$-18.4M
$-55.7M
Q4 22
$-8.2M
Gross Margin
ASTS
ASTS
XFOR
XFOR
Q4 25
Q3 25
Q1 25
83.6%
Q1 24
Q4 23
Q3 23
Q2 23
Q4 22
200.0%
Operating Margin
ASTS
ASTS
XFOR
XFOR
Q4 25
-175.0%
Q3 25
-1109.0%
Q1 25
-32.8%
Q1 24
Q4 23
Q3 23
Q2 23
Q4 22
2522300.0%
Net Margin
ASTS
ASTS
XFOR
XFOR
Q4 25
-136.2%
Q3 25
-833.7%
Q1 25
1.0%
Q1 24
Q4 23
Q3 23
Q2 23
Q4 22
822900.0%
EPS (diluted)
ASTS
ASTS
XFOR
XFOR
Q4 25
Q3 25
Q1 25
$0.04
Q1 24
$-7.77
Q4 23
Q3 23
$-0.01
Q2 23
$-0.33
Q4 22

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASTS
ASTS
XFOR
XFOR
Cash + ST InvestmentsLiquidity on hand
$4.3B
$40.3M
Total DebtLower is stronger
$75.0M
Stockholders' EquityBook value
$2.4B
$22.9M
Total Assets
$5.0B
$130.0M
Debt / EquityLower = less leverage
3.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASTS
ASTS
XFOR
XFOR
Q4 25
$4.3B
Q3 25
$2.4B
Q1 25
$40.3M
Q1 24
$60.5M
Q4 23
$155.3M
Q3 23
$251.7M
$131.6M
Q2 23
$372.9M
$136.4M
Q4 22
$469.3M
Total Debt
ASTS
ASTS
XFOR
XFOR
Q4 25
Q3 25
Q1 25
$75.0M
Q1 24
$55.0M
Q4 23
Q3 23
$55.0M
Q2 23
$4.6M
$32.5M
Q4 22
$4.8M
Stockholders' Equity
ASTS
ASTS
XFOR
XFOR
Q4 25
$2.4B
Q3 25
$1.6B
Q1 25
$22.9M
Q1 24
$1.0M
Q4 23
$213.6M
Q3 23
$287.2M
$67.6M
Q2 23
$335.9M
$67.5M
Q4 22
$359.8M
Total Assets
ASTS
ASTS
XFOR
XFOR
Q4 25
$5.0B
Q3 25
$2.6B
Q1 25
$130.0M
Q1 24
$112.2M
Q4 23
$360.9M
Q3 23
$402.1M
$173.3M
Q2 23
$408.5M
$173.4M
Q4 22
$438.4M
Debt / Equity
ASTS
ASTS
XFOR
XFOR
Q4 25
Q3 25
Q1 25
3.27×
Q1 24
53.09×
Q4 23
Q3 23
0.81×
Q2 23
0.01×
0.48×
Q4 22
0.01×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASTS
ASTS
XFOR
XFOR
Operating Cash FlowLast quarter
$65.0M
$-12.4M
Free Cash FlowOCF − Capex
$-330.7M
FCF MarginFCF / Revenue
-609.0%
Capex IntensityCapex / Revenue
728.7%
0.0%
Cash ConversionOCF / Net Profit
-43.86×
TTM Free Cash FlowTrailing 4 quarters
$-790.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASTS
ASTS
XFOR
XFOR
Q4 25
$65.0M
Q3 25
$-64.5M
Q1 25
$-12.4M
Q1 24
$-33.6M
Q4 23
$-24.9M
Q3 23
$-36.1M
$-68.8M
Q2 23
$-50.3M
$-47.9M
Q4 22
$-35.0M
Free Cash Flow
ASTS
ASTS
XFOR
XFOR
Q4 25
$-330.7M
Q3 25
$-302.9M
Q1 25
Q1 24
$-33.7M
Q4 23
$-47.2M
Q3 23
$-109.5M
$-68.8M
Q2 23
$-57.8M
$-47.9M
Q4 22
$-46.5M
FCF Margin
ASTS
ASTS
XFOR
XFOR
Q4 25
-609.0%
Q3 25
-2055.0%
Q1 25
Q1 24
Q4 23
Q3 23
Q2 23
Q4 22
4647400.0%
Capex Intensity
ASTS
ASTS
XFOR
XFOR
Q4 25
728.7%
Q3 25
1617.6%
Q1 25
0.0%
Q1 24
Q4 23
Q3 23
Q2 23
Q4 22
-1143400.0%
Cash Conversion
ASTS
ASTS
XFOR
XFOR
Q4 25
Q3 25
Q1 25
-43.86×
Q1 24
Q4 23
Q3 23
Q2 23
Q4 22

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASTS
ASTS

Products$44.4M82%
Other$7.8M14%
Sat Co$2.1M4%

XFOR
XFOR

Segment breakdown not available.

Related Comparisons